Noel Camba, MD
Cardiovascular Disease · Palos Park, ILNPI 1083668560
Payments from drug & device makers
Across 1,140 payments — averaging $113.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$69K
- Esperion Therapeutics, Inc.$19K
- Chiesi USA, Inc.$15K
- Novartis$8K
- AstraZeneca$8K
- Medtronic$1K
- plus $9K from 35 others
What the payments were for
- Consulting fees$3000%
- Speaking & faculty fees$103,99680%
- Travel & lodging$2,7552%
- Food & beverage$22,11517%
- Education$5720%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$65,887
- NEXLIZET$17,477
- NEXLETOL$17,477
- KENGREAL$13,685
- FARXIGA$5,790
- ENTRESTO$5,300
- BPRO BT AMBULATORY BLOOD PRESSURE MONITORING SYSTEM$465
- Micra$238
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$176
- WAINUA$169
- JenaValve Pericardial TAVR System$162
- COREVALVE EVOLUT R$151
- Impella$126
- LEQVIO$125
- KENGREAL 50MG/10ML L$118
- LifeVest$117
- GENERAL - THERAPIES$106
- LOKELMA$101
How this compares
$129,739 in reported general payments places this provider in the 90th percentile of 932 cardiovascular disease providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 229 | $283,291 |
| EntrestoSacubitril/Valsartan | 171 | $248,169 |
| EliquisApixaban | 142 | $181,593 |
| NexlizetBempedoic Acid/Ezetimibe | 41 | $40,470 |
| Repatha SureclickEvolocumab | 46 | $34,577 |
| VerquvoVericiguat | 21 | $28,878 |
| FarxigaDapagliflozin Propanediol | 18 | $19,467 |
| BrilintaTicagrelor | 16 | $11,985 |
| Amiodarone Hcl | 132 | $6,647 |
| Metoprolol Succinate | 347 | $5,236 |
| Atorvastatin Calcium | 304 | $3,316 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 118 | $3,148 |
| Propranolol Hcl | 167 | $3,032 |
| Clonidine | 26 | $2,847 |
| Propranolol Hcl ErPropranolol Hcl | 46 | $2,588 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $69,013 | $283,291229 claims |
| NovartisEntresto | $8,154 | $248,169171 claims |
| PfizerEliquis | $879 | $181,593142 claims |
| Esperion Therapeutics, Inc.Nexlizet | $19,248 | $40,47041 claims |
| AstraZenecaFarxiga, Brilinta | $7,626 | $31,45334 claims |
| MerckVerquvo | $767 | $28,87821 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 932 cardiovascular disease providers in Illinois.
Other cardiovascular disease in Palos Park
- Benjamin LumicaoChicago$3.7M
- Paul CremerChicago$2.9M
- Lokesh ChandraHazel Crest$2.7M
- Steven LupovitchArlington Heights$2.6M
- Nitasha SarswatChicago$2M
- Alan BrownNaperville$1.5M
- Alexander AdlerPeoria$1.5M
- Clifford KavinskyMaywood$1.4M
- Sanjiv ShahChicago$1.2M
- Sandeep NathanChicago$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.